2021 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $279M | $279M | $294M | $297M | $314M |
Cost of Revenue | $173M | $173M | $178M | $180M | $191M |
Gross Profit | $106M | $106M | $116M | $116M | $123M |
Gross Profit % | 38% | 38% | 39% | 39% | 39% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2021 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $42M | $42M | $41M | $34M | $30M |
Dep. & Amort. | $4.4M | $4.4M | $3.4M | $3.4M | $3.9M |
Def. Tax | $1.5M | $1.5M | -$480K | $1.4M | -$346K |
Stock Comp. | $10M | $10M | $10M | $11M | $20M |
Chg. in WC | -$11M | -$11M | $6.1M | -$13M | -$6M |
2021 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $46M | $46M | $30M | $21M | $16M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $46M | $46M | $30M | $21M | $16M |
Receivables | $51M | $51M | $48M | $52M | $57M |
Inventory | $0 | $0 | $0 | $0 | $0 |
Q1 2025 revenues before reimbursements were $76.2M (up 1% YoY), and adjusted EPS was $0.41, both near the high end of guidance; results were driven by strong GenAI engagement growth, partially offset by weakness in OneStream and e-procurement practices.
GenAI-related offerings (AI Explorer and ZBrain platforms) are highly differentiated, driving higher gross margins and positioning the company for enterprise-wide, end-to-end AI transformation projects; GenAI consulting and implementation revenue in the GSBT segment grew 13% YoY excluding weaker practices.
Adjusted gross margin improved to 43.4% (from 41.4% YoY), and adjusted EBITDA was $15.7M (20.7% of revenues before reimbursements); GAAP net income was $3.1M ($0.11 per share), impacted by non-cash stock compensation and acquisition-related expenses.
Q2 2025 guidance: revenues before reimbursements expected between $76M–$77.5M, adjusted EPS of $0.37–$0.39, adjusted gross margin of 43–44%, and adjusted EBITDA margin of 21–22%; cash flow from operations expected to increase sequentially.
Strategic focus remains on expanding GenAI capabilities, scaling implementation capacity, and leveraging joint ventures (notably with ZBrain) to drive ARR growth; licensing of AI Explorer is expected to begin in July, with meaningful impact anticipated for FY25 results.